Dengue vaccine fiasco leads to criminal charges for.
Dengue Research Group With the increase in incidence of dengue in the country that led to increased awareness about the disease, the Dengue Study Group was organized some twenty five years ago. Following epidemiological, entomological, virological and clinical studies, the group embarked on studies on the prevention of dengue, particularly on vaccination and vector control.
The purpose of this Special Issue “Research, advances, challenges and perspectives in the development of vaccines against Dengue, Zika and Chikungunya viruses” is to present the latest research results that advance our knowledge on the progress conception of vaccine strategies against these arboviruses.
A vaccine must be protective for all four serotypes of dengue and be cost-effective. Many approaches to developing candidate vaccines have been employed. The candidates include live attenuated tetravalent vaccines, chimeric tetravalent vaccines based on attenuated dengue virus or Yellow Fever 17D, and recombinant DNA vaccines based on flavivirus and non-flavivirus vectors.
Modelers from Sanofi Pasteur have predicted that this vaccine has the potential to reduce by about 50% the disease burden within 5 years when 20% of an endemic country population is vaccinated, thus achieving a World Health Organization dengue prevention goal. In this paper, mathematical modeling is used to investigate the impact of the newly.
Takeda’s dengue milestone is a time for cautious optimism GlobalData Healthcare 5 February 2019 On 29 January, Takeda announced that its investigational live-attenuated dengue vaccine, TAK-003, successfully achieved its primary endpoint in the pivotal Phase III TIDES (DEN-301) study.
The second tissue-culture-passaged dengue vaccine was developed at the Walter Reed Army Institute of Research (WRAIR). The WRAIR-produced tetravalent dengue vaccine initial formulation also showed problems of unbalanced immunogenicity and reactogenicity (Sun et al. 2003).
In the per-protocol analyses, vaccine efficacy was 80.2% (95% CI, 73.3 to 85.3; 61 cases of virologically confirmed dengue in the vaccine group vs. 149 cases in the placebo group), with 95.4%.